The discovery of new therapeutic uses for drugs that have been developed for other indications is known as drug repurposing. The considerable risks inherent in development are greatly reduced because the repurposed drug has been used in a large number of patients often for many years. This means that it has a well-known safety and pharmacokinetic profile. Moreover, the pharmacology, toxicology, formulation and early clinical trials have been completed greatly reducing costs and shortening the pathway to market. It is now accepted that repurposing offers a much better risk-return trade-off compared with other drug development strategies.
View Top Employees from Xenexus Pharmaceuticals Pty LtdWebsite | http://xenexus.com.au |
Revenue | $5 million |
Employees | View employees |
Address | 40 Mount St, North Sydney, New South Wales 2060, AU |
Phone | +61 2 8415 9838 |
Industry | Pharmaceutical Manufacturing, Manufacturing General, Manufacturing |
Competitors | MARIPOSA HEALTH LIMITED, Neuren Pharmaceuticals, NeuroScientific Biopharmaceuticals Ltd |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Xenexus Pharmaceuticals Pty Ltd employee's phone or email?
The Xenexus Pharmaceuticals Pty Ltd annual revenue was $5 million in 2023.
Xenexus Pharmaceuticals Pty Ltd is based in North Sydney, New South Wales.
The NAICS codes for Xenexus Pharmaceuticals Pty Ltd are [32541, 3254, 325, 32].
The SIC codes for Xenexus Pharmaceuticals Pty Ltd are [283, 28].